about
Antimalarial exposure delays Plasmodium falciparum intra-erythrocytic cycle and drives drug transporter genes expressionPfMDR1: mechanisms of transport modulation by functional polymorphismsNovel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistanceA crucial piece in the puzzle of the artemisinin resistance mechanism in Plasmodium falciparum.A new molecular surveillance system for leishmaniasisDrug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance.Complex polymorphisms in the Plasmodium falciparum multidrug resistance protein 2 gene and its contribution to antimalarial response.Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective studyDrug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America.pfmdr1 amplification is related to increased Plasmodium falciparum in vitro sensitivity to the bisquinoline piperaquineAssessing the cost-benefit effect of a Plasmodium falciparum drug resistance mutation on parasite growth in vitro.Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphismsCa(2+) monitoring in Plasmodium falciparum using the yellow cameleon-Nano biosensor.Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, TanzaniaDNA from pre-erythrocytic stage malaria parasites is detectable by PCR in the faeces and blood of hosts.Artemisinin resistance in Plasmodium falciparum: what is it really?Travellers as sentinels: Assaying the worldwide distribution of polymorphisms associated with artemisinin combination therapy resistance in Plasmodium falciparum using malaria cases imported into Scotland.Single nucleotide polymorphisms in Plasmodium falciparum V type H(+) pyrophosphatase gene (pfvp2) and their associations with pfcrt and pfmdr1 polymorphisms.Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity.Rapid diagnostic tests for molecular surveillance of Plasmodium falciparum malaria -assessment of DNA extraction methods and field applicability.Duffy phenotype and Plasmodium vivax infections in humans and apes, Africa.Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa.Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa.Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial.Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6).The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa.Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y.Multiplex PCR-RFLP methods for pfcrt, pfmdr1 and pfdhfr mutations in Plasmodium falciparum.Dynamics of Plasmodium falciparum selection after artemether-lumefantrine treatment in Africa.Dosage of Single Low-Dose Primaquine to Stop Malaria TransmissionThe Vietnamese Khin Population Harbors Particular N-Acetyltransferase 2 Allele FrequenciesPharmacogenetic tools for malaria and TB in the Developing WorldMultigenic architecture of piperaquine resistance trait in Plasmodium falciparum
P50
Q28475290-4E27FAF0-7F6D-4864-A365-4BA428229EEAQ28476753-7EF20034-086C-48A8-8E92-20F94C52F933Q28478286-4D6A7838-B06A-407B-9F0A-A85420A55C8EQ33361130-51438894-5CBA-46CC-B7B8-AE408C68D91AQ33719583-0F788CF5-C0F4-40DF-A905-602CD8F9EBE2Q34453540-033122AB-4B02-44ED-AC71-0665CEC18AA2Q34597342-663529C1-D593-4209-A91A-7DF3A5E303B1Q34728230-37C0F5EC-C14E-42B8-89B6-B67C01C0ADB7Q35698213-AA65FCDB-B895-494D-861D-5906528ACCD0Q36086426-48749D26-9616-4BCF-A929-026D33F45A0CQ36558529-AF9E953A-3EEB-4166-B616-D47E5BD140E0Q36584636-1E4127AC-5976-45F2-8F4A-5B8B5311F5CCQ36719348-B9969409-0EB9-497D-BB41-5585CF8D82ADQ37066203-AD5FE3F9-1E76-4B6F-B983-3061DAB87F32Q38857164-644AC812-7F22-4D84-8BBF-B29B61016F17Q39003417-34DAAE68-80CF-40A8-82AC-94C31AF2C8D7Q39088090-E5675D43-4071-4AC4-A985-F2A1CAD7CED1Q39112469-88D58EC0-6349-45C5-8162-BC733847F263Q39552647-7533F292-74E5-42FE-96F4-D4A1ACE8AD74Q41861482-CF524BC0-CACB-42BE-AAF8-A7A00C00D745Q42425689-59BB3E81-72A1-4828-A9F4-717EA49DB8C1Q42635798-1665B98A-2F79-4780-B63E-A2B868E8F925Q43734691-A5F75EA9-E423-43E1-B845-596FA1E97B30Q43940693-B77FA6DD-8EF8-47FE-8E4D-92B9EC33D66DQ43944680-E324F4BF-15C0-4223-B5C5-5A326923F072Q43945706-36B3DE57-6456-426D-8CCE-FBD4F1A79E65Q46791619-C0F4E1CC-5288-4DD5-870B-99B7ACB4E859Q46930127-8E76CE9B-88F0-4B7A-9B6A-A5CD17F95A07Q48005828-27A03BC5-6CC9-43E9-A42A-405402625522Q56380737-1D1D9A0E-7773-4395-8BA8-C0E5E9D695C8Q58809133-86D713FA-4792-4255-B689-D12726C1739CQ59294215-D2646AD2-5769-4744-9859-94493E979DFFQ92248489-1C349BDC-9CE1-4849-A063-D477B9C8506E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pedro E Ferreira
@es
Pedro E Ferreira
@nl
Pedro E Ferreira
@sl
Pedro E. Ferreira
@en
type
label
Pedro E Ferreira
@es
Pedro E Ferreira
@nl
Pedro E Ferreira
@sl
Pedro E. Ferreira
@en
prefLabel
Pedro E Ferreira
@es
Pedro E Ferreira
@nl
Pedro E Ferreira
@sl
Pedro E. Ferreira
@en
P106
P1153
55427200100
P21
P31
P496
0000-0002-2682-7722